Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16034913 | 0.94 | HSD11B1 (0.38) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035252 | 0.88 | HSD11B1 (0.42) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035757 | 0.88 | HSD11B1 (0.39) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16034892 | 0.85 | HSD11B1 (0.42) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035332 | 0.85 | HSD11B1 (0.40) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035155 | 0.85 | HSD11B1 (0.38) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035128 | 0.84 | HSD11B1 (0.40) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16036893 | 0.83 | HSD11B1 (0.41) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035250 | 0.82 | HSD11B1 (0.38) | HSD11B1DHFRNR1H4 | |
| Bicarbonate SCHEMBL18783217 | 0.81 | HSD11B1 (0.39) | HSD11B1DHFRNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970327-B1 | OXABICYCLO [2.2.2]ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2970327-B1 | OXABICYCLO [2.2.2]ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| US-8962660-B2 | Oxabicyclo [2.2.2] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962660-B2 | Oxabicyclo [2.2.2] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962660-B2 | Oxabicyclo [2.2.2] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2014151247-A1 | OXABICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275173-A1 | OXABICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| US-20140275173-A1 | OXABICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| US-20140275173-A1 | OXABICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275173-A1 | OXABICYCLO [2.2.2] ACID GPR120 MODULATORS | GPR180, GPR52, GPR55 | HSD11B1 584/4885DHFR 3433/4885NR1H4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.